Der Gastroenterologe

, Volume 14, Issue 2, pp 149–150 | Cite as

Mitteilungen der GARPS

Mitteilungen der GARPS


  1. 1.
    Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 69:896–904CrossRefGoogle Scholar
  2. 2.
    Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65:1557–1565CrossRefGoogle Scholar
  3. 3.
    Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C et al (2018) Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation. J Am Gastroenterol AssocGoogle Scholar
  4. 4.
    Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153CrossRefGoogle Scholar
  5. 5.
    Pais R, Redheuil A, Cluzel P, Ratziu V, Giral P (2018) Relationship between fatty liver, specific and multiple-site atherosclerosis and 10-year Framingham Score. HepatologyGoogle Scholar
  6. 6.
    Schmidt FP, Zimmermann T, Wenz T, Schnorbus B, Ostad MA, Feist C et al (2018) Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. Int J Cardiol 271:296–300CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Personalised recommendations